Literature DB >> 14043483

HEMOLYTIC DISEASE ASSOCIATED WITH THE PRODUCTION OF ABNORMAL HEMOGLOBIN AND INTRAERYTHROCYTIC HEINZ BODIES.

S SHIBATA, I IUCHI, T MIYAJI, S UEDA, I TAKEDA.   

Abstract

Entities:  

Keywords:  ADOLESCENCE; BLOOD PROTEIN ELECTROPHORESIS; CHROMATOGRAPHY; ERYTHROCYTES; GENETICS, HUMAN; HEMOGLOBINS, ABNORMAL; PIGMENTATION DISORDERS; URINE

Mesh：

Substances：

Year:  1963        PMID： 14043483

Source DB:  PubMed          Journal:  Nihon Ketsueki Gakkai Zasshi        ISSN： 0001-5806


× No keyword cloud information.
  7 in total

1.  HEREDITARY HEINZ-BODY ANAEMIA, THROMBOCYTOPENIA, AND HAEMOGLOBINOPATHY (HB KOELN) IN A GLASGOW FAMILY.

Authors:  H E HUTCHISON; P H PINKERTON; P WATERS; H LEHMANN; D BEALE; A S DOUGLAS
Journal:  Br Med J       Date:  1964-10-31

2.  Symposium: Haemolytic Anaemias.

Authors:  E R Huehns
Journal:  Proc R Soc Med       Date:  1965-07

3.  Studies of hemoglobin denaturation and Heinz body formation in the unstable hemoglobins.

Authors:  C C Winterbourn; R W Carrell
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

4.  Congenital Heinz-body haemolytic anaemia due to haemoglobin Hammersmith.

Authors:  N K Shinton; H P Williams; D C Thursby-Pelham
Journal:  Postgrad Med J       Date:  1969-09       Impact factor: 2.401

5.  De novo mutations producing unstable hemoglobins or hemoglobins M : I. Establishment of a Depository and use of data to test for an association of de novo mutation with advanced parental age.

Authors:  G Stamatoyannopoulos; P E Nute; M Miller
Journal:  Hum Genet       Date:  1981-10       Impact factor: 4.132

6.  Altered sulfhydryl reactivity of hemoglobins and red blood cell membranes in congenital Heinz body hemolytic anemia.

Authors:  H S Jacob; M C Brain; J V Dacie
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

7.  Hemoglobin Hasharon (alpha-2-47 his(CD5)beta-2): a hemoglobin found in low concentration.

Authors:  S Charache; A M Mondzac; U Gessner
Journal:  J Clin Invest       Date:  1969-05       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.